

# Dickran Kazandjian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5550785/publications.pdf>

Version: 2024-02-01

26  
papers

1,184  
citations

840119

11  
h-index

610482

24  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1927  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and prospective antibody-based therapies in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 41-47.	0.8	2
2	The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.. <i>Seminars in Oncology</i> , 2022, 49, 3-10.	0.8	3
3	Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. <i>Leukemia and Lymphoma</i> , 2022, 63, 2413-2421.	0.6	1
4	Modern Myeloma Therapy + Sustained Minimal Residual Disease = (Functional) Cure!. <i>Journal of Clinical Oncology</i> , 2022, 40, 2863-2866.	0.8	5
5	Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. <i>JAMA Oncology</i> , 2021, 7, 132.	3.4	21
6	Diagnostic performance of 18 F-FDG PET/CT compared to standard skeletal survey for detecting bone destruction in smoldering multiple myeloma: time to move forward. <i>British Journal of Haematology</i> , 2021, 193, 125-128.	1.2	2
7	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. <i>Oncologist</i> , 2021, 26, 288-e541.	1.9	10
8	A new era of novel immunotherapies for multiple myeloma. <i>Lancet</i> , 2021, 398, 642-643.	6.3	6
9	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. <i>JAMA Oncology</i> , 2021, 7, 1678.	3.4	12
10	Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia. <i>Seminars in Oncology</i> , 2021, , .	0.8	0
11	Melphalan Flufenamide: a Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 101.	0.1	0
12	The role of high-dose melphalan with autologous stem cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020, 191, 692-703.	1.2	23
13	The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies – back to the future!. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101150.	0.7	7
14	State of the science in smoldering myeloma: Should we be treating in the clinic?. <i>Seminars in Oncology</i> , 2019, 46, 112-120.	0.8	11
15	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 15.	2.8	30
16	Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 559-568.	0.3	8
17	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. <i>JAMA Oncology</i> , 2018, 4, 1781.	3.4	33
18	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. <i>Blood</i> , 2018, 132, 1957-1957.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1â€“defined disease progression in clinical trials. <i>Seminars in Oncology</i> , 2017, 44, 3-7.	0.8	83
20	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017, 1, 1911-1918.	2.5	37
21	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 974-980.	1.9	64
22	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. <i>Seminars in Oncology</i> , 2016, 43, 682-689.	0.8	53
23	Multiple myeloma epidemiology and survival: A unique malignancy. <i>Seminars in Oncology</i> , 2016, 43, 676-681.	0.8	492
24	Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 4527-4527.	0.6	4
25	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 746.	3.4	266
26	Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 578-87.	0.3	9